{"id":31397,"date":"2025-05-07T13:37:00","date_gmt":"2025-05-07T13:37:00","guid":{"rendered":"https:\/\/new.tabukpharmaceuticals.com\/?p=31397"},"modified":"2025-08-24T16:36:51","modified_gmt":"2025-08-24T16:36:51","slug":"tabuk-pharmaceuticals-expands-strategic-partnership-with-hk-inno-n-to-include-additional-mena-markets-for-k-cab-tegoprazan","status":"publish","type":"post","link":"https:\/\/www.tabukpharmaceuticals.com\/ar\/tabuk-pharmaceuticals-expands-strategic-partnership-with-hk-inno-n-to-include-additional-mena-markets-for-k-cab-tegoprazan\/","title":{"rendered":"\u062a\u0648\u0633\u0639 \u0634\u0631\u0643\u0629 \u062a\u0628\u0648\u0643 \u0644\u0644\u0623\u062f\u0648\u064a\u0629 \u0634\u0631\u0627\u0643\u062a\u0647\u0627 \u0627\u0644\u0627\u0633\u062a\u0631\u0627\u062a\u064a\u062c\u064a\u0629 \u0645\u0639 \u0634\u0631\u0643\u0629 HK inno.N \u0644\u062a\u0634\u0645\u0644 \u0623\u0633\u0648\u0627\u0642\u064b\u0627 \u0625\u0636\u0627\u0641\u064a\u0629 \u0641\u064a \u0645\u0646\u0637\u0642\u0629 \u0627\u0644\u0634\u0631\u0642 \u0627\u0644\u0623\u0648\u0633\u0637 \u0648\u0634\u0645\u0627\u0644 \u0623\u0641\u0631\u064a\u0642\u064a\u0627 \u0644\u062f\u0648\u0627\u0621 K-CAB\u00ae (\u062a\u064a\u063a\u0648\u0628\u0631\u0627\u0632\u0627\u0646)"},"content":{"rendered":"\n

Riyadh, Saudi Arabia<\/strong> \u2013 [May 7 2025] \u2014 Tabuk Pharmaceuticals, a leading Saudi pharmaceutical company with a strong regional footprint across the Middle East and North Africa (MENA), announced today the expansion of its strategic collaboration with HK inno.N for the innovative gastroesophageal reflux disease (GERD) treatment, K-CAB\u00ae (Tegoprazan).
This expansion builds upon the exclusive License and Supply Agreement signed in early 2024 between Tabuk Pharmaceuticals and HK inno.N, originally covering 10 MENA countries. Under the newly expanded agreement, six additional countries\u2014Egypt, Sudan, Ethiopia, Morocco, Yemen, and Libya\u2014are now included, significantly strengthening Tabuk\u2019s footprint and patient reach across the region.<\/p>\n\n\n\n

\n

\u201cAs part of our vision to bring advanced, accessible, and effective treatments to patients
in the MENA region, we are proud to deepen our partnership with HK inno.N\u201d <\/p>\n<\/blockquote>\n\n\n\n

said Ismail Shehada, CEO of Tabuk Pharmaceuticals. <\/p>\n\n\n\n

\n

\u201cK-CAB\u00ae is an important addition to our portfolio, and this expansion underscores our commitment to improving patient outcomes by offering best-in-class solutions across wider geographies.\u201d<\/p>\n<\/blockquote>\n\n\n\n

Kwak Dal-won, CEO of HK inno.N, commented,<\/p>\n\n\n\n

\n

\u201cWith this agreement, we have reached 53 countries, more than halfway to our goal of reaching 100 countries by 2028. We will continue to work closely with our partners in each country to establish K-CAB as a paradigm-shifting new drug for the treatment of GERD worldwide.\u201d
<\/p>\n<\/blockquote>\n\n\n\n

Tabuk Pharmaceuticals will leverage its robust distribution, regulatory, and commercial capabilities to accelerate the availability and adoption of K-CAB\u00ae in these newly added markets. With this agreement, K-CAB\u00ae has now reached 54 countries globally, further solidifying its status as a leading global therapy in GERD treatment.<\/p>\n\n\n\n


K-CAB\u00ae , developed by HK inno.N, is South Korea\u2019s 30th new drug and belongs to the Potassium-Competitive Acid Blocker (P-CAB) class. The product offers rapid onset of action, sustained efficacy, and proven safety for long-term use, with multiple formulations and approved indications.<\/p>\n\n\n\n


This agreement reinforces Tabuk Pharmaceuticals\u2019 leadership in bringing global pharmaceutical innovation to the region and highlights its enduring commitment to expanding healthcare access across MENA.<\/p>\n","protected":false},"excerpt":{"rendered":"

Riyadh, Saudi Arabia \u2013 [May 7 2025] \u2014 Tabuk Pharmaceuticals, a leading Saudi pharmaceutical company with a strong regional footprint across the Middle East and North Africa (MENA), announced today the expansion of its strategic collaboration with HK inno.N for the…<\/p>\n","protected":false},"author":7,"featured_media":31006,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[61],"tags":[],"class_list":["post-31397","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-releases"],"_links":{"self":[{"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/posts\/31397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/comments?post=31397"}],"version-history":[{"count":1,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/posts\/31397\/revisions"}],"predecessor-version":[{"id":31398,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/posts\/31397\/revisions\/31398"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/media\/31006"}],"wp:attachment":[{"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/media?parent=31397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/categories?post=31397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.tabukpharmaceuticals.com\/ar\/wp-json\/wp\/v2\/tags?post=31397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}